What Compai Pharma does

Compai Pharma is a Singapore-headquartered, B2B pharmaceutical distributor and commercialization-services provider operating across Malaysia and Singapore. Founded in 2017 as part of the Nava conglomerate's healthcare diversification strategy, the company holds the requisite Wholesale Dealer's Licence (NPRA, Malaysia), GDP Certification, and Therapeutic Products Importer's and Wholesaler's Licences (HSA, Singapore), enabling licensed distribution of prescription pharmaceuticals, medical devices, and diagnostics.

The company's product platform is assembled entirely through strategic distribution partnerships with global healthcare innovators rather than through proprietary R&D. The portfolio spans Women's Health (Cumlaude Lab intimate care portfolio across adolescence to menopause; CELOX Medical for postpartum hemorrhage control; LO.LI Pharma for reproductive health), Oncology (Guardant Health's Guardant360 liquid biopsy, Guardant Reveal tissue-free MRD test, and Guardant Tissue Next), Gastroenterology (Amili's Faecal Microbiota Transplant services for CDI, IBD, IBS, and gut-brain axis conditions), Rapid Diagnostics (Actim point-of-care tests for influenza, pancreatitis, calprotectin, fecal blood, and CRP), and Biosidus biosimilars. Compai Pharma's core commercial capability is a territory-based Product Specialist field force covering Key Accounts, retail pharmacies, hospitals, and GP clinics in Malaysia and Singapore, supplemented by an integrated services layer (Medical Affairs, Sales & Marketing, Market Access, Regulatory, and Distribution & Logistics) offered to international healthcare partners seeking Southeast Asia market entry.

The firm monetizes through distribution markups on transaction-fee sales of registered products and through professional-services revenue from commercialization engagements. End customers include hospitals, pharmacies, and clinicians; principal counterparties (i.e., paymasters and supply sources) are global pharmaceutical and medical-device companies using Compai Pharma as their local distribution and commercialization partner.

Name

Compai Pharma

Legal name

Compai Pharma Sdn. Bhd. / Pte. Ltd.

Website

https://compaipharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Compai Pharma is a Singapore-based, Nava-owned B2B pharmaceutical distributor and commercialization-services partner operating across Malaysia and Singapore, distributing global brands in Women's Health, Oncology, Gastroenterology, and Rapid Diagnostics through a GDP-licensed network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)

Keywords

• Pharmaceutical distribution
• Medical device sales
• Oncology diagnostics
• Women's health products
• Clinical trial supply

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Distribution: B2B pharmaceutical distribution of registered healthcare and pharmaceutical products in Malaysia and Singapore. Licensed wholesale dealer and importer distributing products sourced from licensed manufacturers and authorized brand holders.
2. Services Revenue: Revenue generated from providing comprehensive commercialization services including Medical Affairs, Sales & Marketing, Market Access, Regulatory Expertise, and Distribution & Logistics support to pharmaceutical partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Compai Pharma is a licensed B2B pharmaceutical and medical device distributor operating in Malaysia and Singapore. It commercializes a portfolio spanning women's health, oncology diagnostics, gastroenterology, blood management, hematology, and infectious disease through strategic partnerships with global innovators such as Guardant Health, Cumlaude Lab, Amili, Actim, Celox Medical, Biosidus, and LO.LI Pharma. Its offering combines product distribution with end-to-end commercialization services including medical affairs, sales and marketing, market access, regulatory expertise, and GDP-compliant logistics.

Product overview

Compai Pharma operates as a B2B pharmaceutical distributor offering a diversified portfolio of healthcare products across four therapeutic areas: Women's Health (through Cumlaude Lab sub-brand), Oncology (through Guardant Health partnership), Gastroenterology (Actim rapid diagnostics and Amili Faecal Microbiota Transplant), and Women's Health Emergency (Celox Medical for postpartum hemorrhage). The Women's Health portfolio under Cumlaude Lab includes intimate care products (cleansing gels, mousses, moisturisers), ovules, and menopause treatments. The Oncology portfolio features Guardant360 Liquid Biopsy (739-gene comprehensive genomic profiling), Guardant Reveal (tissue-free MRD detection), and Guardant Tissue Next for tissue sequencing. Actim rapid diagnostics cover influenza, pancreatitis, calprotectin, fecal blood, and CRP testing. FMT offers microbiome restoration therapy for CDI, IBD, IBS, and gut-brain axis conditions. These products are distributed exclusively in Malaysia and Singapore through strategic partnerships with international healthcare leaders.

Differentiator

Problem solved

Functional benefit

Products and services

• Cumlaude Lab Women's Intimate Care Products A scientifically backed portfolio of intimate hygiene and care products (cleansing gels, mousses, moisturizers, ovules, and toning treatments) for women across life stages from adolescence through menopause, available in Malaysia and Singapore.
• Guardant360 Liquid Biopsy Liquid biopsy test analyzing 739 genes for comprehensive genomic profiling of solid tumors (lung, breast, colorectal) to identify actionable mutations and guide targeted therapy selection for advanced cancer patients.
• Guardant Reveal Tissue-free minimal residual disease (MRD) test that detects circulating tumor DNA for early-stage colorectal, breast, and lung cancers, supporting recurrence monitoring and treatment decisions.
• Guardant Tissue Next Tissue-based next-generation sequencing test for comprehensive genomic profiling of tumor tissue samples, complementing Guardant's liquid biopsy portfolio.
• Actim Rapid Diagnostic Tests Point-of-Care rapid diagnostic tests developed by Medix Biochemica (Finland) covering influenza A&B differentiation, acute pancreatitis (trypsinogen-2), intestinal inflammation (calprotectin), fecal occult blood, and CRP, delivering results in 5-10 minutes without laboratory equipment.
• Faecal Microbiota Transplant (FMT) Therapy Anaerobically processed FMT preparations from rigorously screened donors, available as capsules or colonoscopy administration, used for Clostridioides difficile infection, inflammatory bowel disease, irritable bowel syndrome, and gut-brain axis conditions including autism spectrum disorder and Parkinson's disease.
• Celox Medical Hemostatic Solutions Fast-acting, safe, clinically effective, and versatile easy-to-use hemostatic products designed for control of postpartum hemorrhage and other maternal care bleeding scenarios.
• Biosidus Biosimilars Biosimilar pharmaceutical products from a market-leading biosimilars producer distributed to hospitals and healthcare providers in Malaysia and Singapore.
• LO.LI Pharma Reproductive Health Products Reproductive health products from LO.LI Pharma distributed to healthcare providers in Malaysia, supporting women's reproductive well-being.
• Pharmaceutical Commercialization Services End-to-end commercialization support for international healthcare partners entering Malaysia and Singapore, including medical affairs, sales and marketing, market access, regulatory expertise, strategic partnerships, and GDP-compliant distribution and logistics.

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eight partnerships are on record, tiered core, major and supporting.

• Cumlaude LabcoreStrategic or Co-development PartnerStrategic partnership with Cumlaude Lab (founded 1998 by medical and pharmaceutical experts) for women's intimate health products. Compai Pharma distributes Cumlaude Lab's scientifically backed products for intimate care, pregnancy, and menopause across Malaysia and Singapore.
• Guardant HealthcoreStrategic or Co-development PartnerAlliance with Guardant Health bringing precision oncology solutions to Malaysia. Products include Guardant360 Liquid Biopsy (739 genes, comprehensive genomic profiling for solid tumors) and Guardant Reveal (tissue-free MRD detection for colorectal, breast, and lung cancers).
• AmilicoreStrategic or Co-development PartnerPartnership with Amili, Southeast Asia's first FMT stool bank, for Faecal Microbiota Transplant treatments. Amili specializes in anaerobic processing of FMT preparations from rigorously screened donors. Partnership provides advanced treatments for CDI, IBD, IBS, and explores gut-brain axis applications.
• CELOX MedicalmajorStrategic or Co-development PartnerStrategic partnership with CELOX Medical to address postpartum hemorrhage (PPH), a leading cause of maternal mortality. CELOX provides fast-acting, safe, clinically effective, and versatile easy-to-use hemostatic solutions for maternal care.
• Actim (Medix Biochemica)majorStrategic or Co-development PartnerPartnership with Actim (developed and manufactured in Finland by Medix Biochemica) for rapid Point-of-Care diagnostics. Products include Actim Influenza A&B, Actim Pancreatitis, Actim Calprotectin, Actim Fecal Blood, and Actim CRP for quick, evidence-based clinical decisions.
• BiosidussupportingStrategic or Co-development PartnerPartnership with Biosidus, a market leader in production and commercialization of biosimilars. Brings biosimilar products to the Malaysian and Singapore markets.
• LO.LI PharmasupportingStrategic or Co-development PartnerPartnership with LO.LI Pharma, committed to making a lasting impact on women's reproductive health and well-being. Provides reproductive health products to the Malaysian market.
• Nava (Parent Company)coreOthersNava is a diversified company with global footprint across Asia and Africa, with businesses in Ferro-alloy manufacturing, Energy, Mining, Agribusiness, and O&M services for over 50 years. Compai Pharma Pte. Ltd. is a fully-owned subsidiary under Nava's diversification strategy into healthcare.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cardinal Health: US-headquartered global pharmaceutical and medical product distributor with growing Asia presence. Comparable to Compai Pharma in core pharma distribution and medical product wholesale, with overlap in serving hospital, pharmacy and specialty customers.
• Cencora (formerly AmerisourceBergen): One of the world's largest pharmaceutical services companies, distributing drugs, specialty products and animal health globally, including through partners in Asia. Comparable to Compai Pharma as a global pharma distribution incumbent; relevant for scale, specialty-pharma capabilities and competitive threat.
• Thermo Fisher Scientific Asia: Global life-sciences and diagnostics company distributing instruments, reagents and clinical diagnostics including oncology and reproductive health across Asia-Pacific. Comparable to Compai Pharma's diagnostics and specialty life-sciences portfolio as a regional distribution channel for advanced healthcare products.
• GE HealthCare Asia: Global medical technology and diagnostics company with significant Asia-Pacific operations distributing imaging, ultrasound, life-care solutions and pharmaceuticals through hospital channels. Comparable to Compai Pharma as a broader healthcare products distributor serving hospitals and specialists in Malaysia and Singapore, though across a much wider portfolio.

Direct peers

• DKSH Holding: Swiss-headquartered Market Expansion Services group with a major Healthcare unit distributing pharmaceuticals, medical devices and consumer health products across Asia, including Malaysia and Singapore. Closely comparable to Compai Pharma as a market-entry partner providing sales, marketing, regulatory and distribution services to global healthcare brands in SEA.
• Sysmex Asia Pacific: Subsidiary of Sysmex Corporation distributing hematology, IVD and clinical diagnostic solutions across Southeast Asia. Comparable to Compai Pharma's diagnostics arm (Actim rapid diagnostics, Guardant liquid biopsy) as a specialty IVD/molecular diagnostics distributor in the same regional markets.
• Zuellig Pharma: One of the largest pharmaceutical and healthcare distributors in Asia, headquartered in Singapore with deep Malaysia and Singapore footprints. Directly comparable to Compai Pharma as a B2B pharma wholesaler serving hospitals, pharmacies and manufacturers across Southeast Asia, though at vastly greater scale and portfolio breadth.
• Pharmaforte: Singapore-based pharmaceutical distribution and marketing company focused on specialty prescription and consumer health products in Southeast Asia. Comparable to Compai Pharma in scale, regional focus (Malaysia/Singapore) and role as a niche distribution partner for international principals.
• Menarini Asia-Pacific: Asia-Pacific arm of the Menarini Group, marketing and distributing pharmaceutical and consumer health products across the region including Malaysia and Singapore. Comparable to Compai Pharma as a specialty pharma distributor leveraging partnerships and a medically-trained field force to commercialize international brands.

Regional players

• DHL Supply Chain Life Sciences: Division of DHL providing GDP-compliant warehousing, cold-chain logistics and distribution services to pharmaceutical and medical device companies across Southeast Asia. Comparable to Compai Pharma's logistics backbone and a potential competitor or partner for principals evaluating regional distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/compai-pharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compai Pharma